BI 765128

BI 765128 is an investigational drug developed by Boehringer Ingelheim for the treatment of diabetic retinopathy, specifically in patients who have undergone panretinal photocoagulation and have diabetic macular ischemia. It is administered as an intravitreal injection directly into the eye. The mechanism of action for BI 765128 has not been defined or disclosed publicly. Clinical trials (notably the PARTRIDGE study) have focused on evaluating its safety, tolerability, and early biological response after single and multiple injections in affected patients. As of August 2023, phase I/II clinical trials were completed with no dose-limiting or drug-related adverse events reported[1][3][6][7].